Nevertheless, triple-negative breast cancer (TNBC) presents potential opportunities for the application of ICIs due to its higher levels of infiltrating lymphocytes, increased tumor mutational burden (TMB), and elevated PD-L1 expression[21-23]. This evidence concerns the gene CD274 and neoplasm.